Combined cord blood and bone marrow transplantation from the same human leucocyte antigen-identical sibling donor for children with malignant and non-malignant diseases

Basit Öğe Kaydı
dc.contributor.authorTucunduva, Luciana
dc.contributor.authorVolt, Fernanda
dc.contributor.authorCunha, Renato
dc.contributor.authorLocatelli, Franco
dc.contributor.authorZecca, Marco
dc.contributor.authorYesilipek, Akif
dc.contributor.authorCaniglia, Maurizio
dc.contributor.authorGuengoer, Tayfun
dc.contributor.authorAksoylar, Serap
dc.contributor.authorFagioli, Franca
dc.contributor.authorBertrand, Yves
dc.contributor.authorAddari, Maria Carmen
dc.contributor.authorde la Fuente, Josu
dc.contributor.authorWiniarski, Jacek
dc.contributor.authorBiondi, Andrea
dc.contributor.authorSengeloev, Henrik
dc.contributor.authorBadell, Isabel
dc.contributor.authorMellgren, Karin
dc.contributor.authorde Heredia, Cristina Diaz
dc.contributor.authorSedlacek, Petr
dc.contributor.authorVora, Ajay
dc.contributor.authorRocha, Vanderson
dc.contributor.authorRuggeri, Annalisa
dc.contributor.authorGluckman, Eliane
dc.date.accessioned2019-10-27T23:01:33Z
dc.date.available2019-10-27T23:01:33Z
dc.date.issued2015
dc.departmentEge Üniversitesien_US
dc.description.abstractUmbilical cord blood (UCB) from an human leucocyte antigen (HLA)-identical sibling can be used for transplantation of patients with malignant and non-malignant diseases. However, the low cellular content of most UCB units represents a limitation to this approach. An option to increase cell dose is to harvest bone marrow (BM) cells from the same donor and infuse them along with the UCB. We studied 156 children who received such a combined graft between 1992 and 2011. Median age was 7years and 78% of patients (n=122) were transplanted for non-malignant diseases, mainly haemoglobinopathies. Acute leukaemia (n=26) was the most frequent malignant diagnosis. Most patients (91%) received myeloablative conditioning. Median donor age was 17years, median infused nucleated cell dose was 244x10(7)/kg and median follow-up was 41months. Sixty-days neutrophil recovery occurred in 96% of patients at a median of 17d. The probabilities of grade-II-IV acute and chronic graft-versus-host disease (GVHD) were 19% and 10%, respectively. Four-year overall survival was 90% (68% malignant; 97% non-malignant diseases) with 3% probability of death. In conclusion, combined UCB and BM transplantation from an HLA-identical sibling donor is an effective treatment for children with malignant and non-malignant disorders with high overall survival and low incidence of GVHD.en_US
dc.description.sponsorshipassociation 'Cordons de vie'; Monacorden_US
dc.description.sponsorshipThe authors thank Chantal Kenzey for helping collecting the data, the association 'Cordons de vie' and Monacord for the financial support, and the transplant centres that contributed patients for this study (listed in alphabetic order by country): Australia - Sydney - The Children's Hospital at Westmead, Austria - Graz - Medical University, Austria - Innsbruck - University Hospital, Austria - Vienna - St. Anna Kinderspital, Belgium - Brussels - Children's University Hospital BMT Unit, Belgium - Brussels - Cliniques Universitaires St. Luc, Belgium - Gent - University Hospital Gent, Czech Republic - Prague - University Hospital Motol, Denmark - Copenhagen - Rigshospitalet, France - Lyon - IHOP, France - Lille - Claude Huriez, France - Nancy - Brabois, France - Paris - Robert Debre, France - Paris - Saint-Louis, Germany - Dusseldorf Universitatsklinikum, Germany - Essen - University Hospital Department of Paediatric Haematology/Oncology, Germany - Hannover - Medical School Department Paediatric Haematology/Oncology, Germany - Heidelberg - University of Heidelberg, Germany - Ulm - Universitat Ulm, Greece - Athens - St. Sophia Children's Hospital, Israel - Jerusalem - Hadassah University Hospital, Israel - Tel-Hashomer - Chaim Sheba Medical Centre, Israel - Tel-Hashomer - Edmond & Lily Safra Children's Hospital, Chaim Sheba Med Centre, Italy - Bologna - Azienda Ospedaliero-Universitaria di Bologna, Italy - Firenze - Azienda Ospedaliero Universitaria Meyer - Ospedale di Careggi, Italy - Genova - Institute G. Gaslini, Italy - Monza Clinica Pediatrica dell' Universita di Milano-Bicocca Ospedale San Gerardo/Fondazione MBBM, Italy - Pavia - Fondazione IRCCS Policlinico San Matteo, Italy - Pisa - Azienda Ospedaliera Universitaria Pisa, Italy - Reggio Calabria - Azienda Ospedaliera Bianchi-Melacrino-Morelli, Italy - Roma - Rome Transplant Network, Italy - Rome-IRRCS Ospedale Pediatrico Bambino Gesu, Italy - Torino - Ospedale Infantile Regina Margherita Onco-Ematologia Pediatrica, Italy - Cagliari-Paediatric Transplant Centre Centro Trapianti di Midollo Osseo Ospedale Microcitemico, Poland - Wroclaw - Wroclaw Medical University, Poland - Wroclaw DCTK, Portugal - Lisbon - Instituto Portugues Oncologia, Spain - Barcelona - Hospital Santa Creui Sant Pau, Spain - Barcelona - Hospital Valld'Hebron, Spain - Malaga - Hospital Carlos Haya, Spain - Barcelona-Hospital Valld'Hebron Unidad de Adultos, Sweden - Gothenberg - Sahlgrenska University Hospital, Sweden - Stockholm - Karolinska University Hospital Children's Hospital, Switzerland - Zurich - University Childrens Hospital, The Netherlands - Leiden - University Hospital, Turkey - Ankara - Hacettepe University Childrens Hospital, Turkey - Antalya - Akdeniz University Medical School, Turkey - Izmir - Ege University, Turkey - Istanbul - Medical Park Goztepe Hospital, Turkey - Istanbul - Medical Park Bahcelievler Hospital Paediatric, United Kingdom - London - Division of Paediatrics St. Mary's Hospital, United Kingdom - Manchester - Department of Paediatric Haematology, United Kingdom - Birmingham - Birmingham Childrens Hospital, United Kingdom - Bristol - Royal Hospital for Children, United Kingdom - Leeds - Mid Yorkshire Hospitals NHS Trust, United Kingdom - London - Great Ormond Street Hospital, United Kingdom - London - St. Mary's Hospital Division of Paediatrics, United Kingdom - Sheffield - Royal Hallamshire Hospital.en_US
dc.identifier.doi10.1111/bjh.13267en_US
dc.identifier.endpage110en_US
dc.identifier.issn0007-1048
dc.identifier.issn1365-2141
dc.identifier.issue1en_US
dc.identifier.pmid25521756en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage103en_US
dc.identifier.urihttps://doi.org/10.1111/bjh.13267
dc.identifier.urihttps://hdl.handle.net/11454/52179
dc.identifier.volume169en_US
dc.identifier.wosWOS:000351446400013en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWiley-Blackwellen_US
dc.relation.ispartofBritish Journal of Haematologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjecthaematopoietic stem cell transplantationen_US
dc.subjectcord blooden_US
dc.subjectbone marrowen_US
dc.titleCombined cord blood and bone marrow transplantation from the same human leucocyte antigen-identical sibling donor for children with malignant and non-malignant diseasesen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu